A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer

George, 2021, New approaches to first-line treatment of advanced renal cell carcinoma, Ther Adv Med Oncol, 13, 10.1177/17588359211034708 National Comprehensive Cancer Network. Kidney cancer (version 4.2023). https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Mitchell, 2018, Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx Renal, Cell, 173, 611, 10.1016/j.cell.2018.02.020 Ricketts, 2018, The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma [correction, Cell Rep. 2018 Jun 19;23:3698], Cell Rep, 23, 313, 10.1016/j.celrep.2018.03.075 Chen, 2016, Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets, Nat Commun, 7, 13131, 10.1038/ncomms13131 Espana-Agusti, 2017, Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis, Nat Commun, 8, 2026, 10.1038/s41467-017-02245-1 Scanlon, 2017, Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity in VHL-deficient human renal cell carcinoma, Oncotarget, 9, 4647, 10.18632/oncotarget.23470 Toro, 2003, Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America, Am J Hum Genet, 73, 95, 10.1086/376435 Linehan, 2013, Molecular pathways: fumarate hydratase-deficient kidney cancer—targeting the Warburg effect in cancer, Clin Cancer Res, 19, 3345, 10.1158/1078-0432.CCR-13-0304 Ueno, 2022, Targeting Krebs-cycle-deficient renal cell carcinoma with poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy, Oncotarget, 13, 1054, 10.18632/oncotarget.28273 Kadoch, 2015, Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics, Sci Adv, 1, e1500447, 10.1126/sciadv.1500447 Msaouel, 2020, Comprehensive molecular characterization identifies distinct genomic and immune hallmarks of renal medullary carcinoma, Cancer Cell, 37, 720, 10.1016/j.ccell.2020.04.002 Lord, 2017, PARP inhibitors: synthetic lethality in the clinic, Science, 355, 1152, 10.1126/science.aam7344 Sulkowski, 2018, Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair, Nat Genet, 50, 1086, 10.1038/s41588-018-0170-4 Stewart, 2018, Development of PARP and immune-checkpoint inhibitor combinations, Cancer Res, 78, 6717, 10.1158/0008-5472.CAN-18-2652 Ding, 2018, PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer, Cell Rep, 25, 2972, 10.1016/j.celrep.2018.11.054 Jiao, 2017, PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression, Clin Cancer Res, 23, 3711, 10.1158/1078-0432.CCR-16-3215 Chabanon, 2021, PBRM1 deficiency confers synthetic lethality to DNA repair inhibitors in cancer, Cancer Res, 81, 2888, 10.1158/0008-5472.CAN-21-0628 Wang, 2017, cGAS is essential for the antitumor effect of immune checkpoint blockade, Proc Natl Acad Sci U S A, 114, 1637, 10.1073/pnas.1621363114 Feng, 2022, PBAF loss leads to DNA damage-induced inflammatory signaling through defective G2/M checkpoint maintenance, Genes Dev, 36, 790, 10.1101/gad.349249.121 Hurvitz, 2020, Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA trial, Oncologist, 25, e439, 10.1634/theoncologist.2019-0493 Motzer, 2019, Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med, 380, 1103, 10.1056/NEJMoa1816047 Choueiri, 2018, Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial, Lancet Oncol, 19, 451, 10.1016/S1470-2045(18)30107-4 Schram, 2023, Avelumab plus talazoparib in patients with brca1/2- or ATM-altered advanced solid tumors: results from JAVELIN BRCA/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial, JAMA Oncol, 9, 29, 10.1001/jamaoncol.2022.5218 Eisenhauer, 2009, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Seymour, 2017, iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics [correction, Lancet Oncol. 2019 May; 20:e242], Lancet Oncol, 18, e143, 10.1016/S1470-2045(17)30074-8 Cheng, 2015, Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology, J Mol Diagn, 17, 251, 10.1016/j.jmoldx.2014.12.006 Turner, 2004, Hallmarks of 'BRCAness' in sporadic cancers, Nat Rev Cancer, 4, 814, 10.1038/nrc1457 Warsow, 2018, Genomic features of renal cell carcinoma with venous tumor thrombus, Sci Rep, 8, 7477, 10.1038/s41598-018-25544-z Chan, 2010, Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment, Cancer Res, 70, 8045, 10.1158/0008-5472.CAN-10-2352 Schettini, 2021, Poly (ADP-ribose) polymerase inhibitors in solid tumours: systematic review and meta-analysis [correction, Eur J Cancer. 2021;153:274], Eur J Cancer, 149, 134, 10.1016/j.ejca.2021.02.035 Agarwal, 2023, TALAPRO-2: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC), J Clin Oncol, 41 Peña-Llopis, 2012, BAP1 loss defines a new class of renal cell carcinoma [correction, Nat Genet. 2012;44:1072], Nat Genet, 44, 751, 10.1038/ng.2323 Hellmann, 2018, Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden, N Engl J Med, 378, 2093, 10.1056/NEJMoa1801946 Rizvi, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348 Jonasch, 2021, Belzutifan for renal cell carcinoma in Von Hippel-Lindau disease, N Engl J Med, 385, 2036, 10.1056/NEJMoa2103425 Motzer, 2020, Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade, Cancer Cell, 38, 803, 10.1016/j.ccell.2020.10.011 Gleeson, 2021, Comprehensive molecular characterization and response to therapy in fumarate hydratase-deficient renal cell carcinoma, Clin Cancer Res, 27, 2910, 10.1158/1078-0432.CCR-20-4367 Albiges, 2014, MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array, Clin Cancer Res, 20, 3411, 10.1158/1078-0432.CCR-13-2173 Vano, 2022, Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial, Lancet Oncol, 23, 612, 10.1016/S1470-2045(22)00128-0 Chen, 2023, Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC), J Clin Oncol, 41, 10.1200/JCO.2023.41.6_suppl.TPS742 Choueiri, 2022, SAMETA: an open-label, three-arm, multicenter, phase III study of savolitinib + durvalumab versus sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma (PRCC), J Clin Oncol, 40, 10.1200/JCO.2022.40.16_suppl.TPS4601 Tannir, 2016, Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial, Eur Urol, 69, 866, 10.1016/j.eururo.2015.10.049 Armstrong, 2016, Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial, Lancet Oncol, 17, 378, 10.1016/S1470-2045(15)00515-X Choi, 2019, Bevacizumab plus erlotinib combination therapy for advanced hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma: a multicenter retrospective analysis in Korean patients, Cancer Res Treat, 51, 1549, 10.4143/crt.2019.086 Voss, 2016, Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma, J Clin Oncol, 34, 3846, 10.1200/JCO.2016.67.9084 Lee, 2022, Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates, J Clin Oncol, 40, 2333, 10.1200/JCO.21.01944 Lee, 2017, Persistent severe hyperlactatemia and metabolic derangement in lethal SDHB-mutated metastatic kidney cancer: clinical challenges and examples of extreme Warburg effect, JCO Precis Oncol, 1 Shah, 2017, Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study, BJU Int, 120, 782, 10.1111/bju.13705 Ryan, 2021, Combination therapy with bortezomib in renal medullary carcinoma: a case series, Clin Genitourin Cancer, 19, e395, 10.1016/j.clgc.2021.08.004